logo

Myriad Genetics Inc. (MYGN)



Trade MYGN now with
  Date
  Headline
3/30/2020 7:19:38 AM Myriad Seeks Japanese Regulatory Approval For BRACAnalysis Diagnostic System
3/23/2020 7:08:29 AM Myriad Genetics Names Louise Phanstiel Chair Of Board
2/11/2020 7:07:33 AM Myriad Genetics Submits SPMA Application To FDA For Its MyChoice CDx Test
2/6/2020 4:08:07 PM Myriad Genetics Q2 Adjusted EPS $0.23 Vs $0.38 last Year
1/22/2020 7:58:14 PM Myriad Submits SPMA For MyChoice CDx With Zejula In First-Line Platinum Responsive Advanced Ovarian Cancer
1/21/2020 7:09:59 AM Myriad Genetics Submits SPMA Application For Its BRACAnalysis CDx Test
1/14/2020 7:20:07 AM Myriad Genetics Names Thomas Slavin SVP Of Medical Affairs At Myriad Oncology
12/30/2019 7:07:34 AM Myriad Receives FDA Approval Of BRACAnalysis CDx As Companion Diagnostic For Lynparza
11/21/2019 7:14:48 AM Myriad Genetics Says Japan's MHLW Approved BRACAnalysis Diagnostic System
11/4/2019 4:11:00 PM Myriad Genetics Q1 Loss/share $0.28 Vs. Loss $0.01 Year Ago
10/21/2019 7:08:16 AM Myriad Genetics Names Mark Pollack Chief Medical Officer Of Myriad Neuroscience, Effective Jan. 15
9/16/2019 7:26:58 AM Myriad Genetics Enters Research Collaboration With University Of Leeds
8/22/2019 7:14:53 AM Myriad Genetics Applauds USPSTF Recommendation On BRCA-Related Cancer Prevention
  
 
>